SLS-004 Lowered Alpha-synuclein Levels in Mice

SLS-004 Lowered Alpha-synuclein Levels in Mice

299005

SLS-004 Lowered Alpha-synuclein Levels in Mice

SLS-004, Seelos Therapeutics’ experimental epigenetic editing therapy for Parkinson’s disease, effectively reduced the production of alpha-synuclein — the protein that accumulates in toxic clumps in Parkinson’s — in the brains of healthy mice. Epigenetic modifications refer to the addition of chemical marks to DNA by a group of specialized enzymes that influence genes’ activities without altering their underlying DNA sequence. In contrast to gene-editing therapies, which add, remove, or change specific DNA sections, epigenetic editing allows…

You must be logged in to read/download the full post.